Representation of Distribution Grid Expansion Costs in Power System Planning

The shift towards clean energy brings about notable transformations to the energy system. In order to optimally plan a future energy system, it is necessary to consider the influence of several sectors as well as the interaction of the transmission grid and distribution grid. The concept of Feasible Operation Region (FOR) is a detailed approach to representing the operational dependencies between the transmission and distribution grid. However, in previous planning procedures, only a simplified expansion of the distribution grids can be taken into account. With the method presented in this paper, a Feasible Planning Region (FPR) is developed, which represents the operational boundaries of the distribution grids for several expansion stages and thus represents an admissible solution space for the planning of distribution grids in systemic planning approaches. It hence enables a more detailed representation of the necessary distribution grid expansion for the integration of distributed technologies in an optimized energy system of the future. In this paper, we present the method by which the FPR is formed and its integration into an energy system planning formulation. In the results, the FPR is presented for different voltage levels, and its use in power system planning is demonstrated

Students' participation in collaborative research should be recognised

Letter to the editor

Intravenous NPA for the treatment of infarcting myocardium early: InTIME-II, a double-blind comparison on of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction

Aims to compare the efficacy and safety of lanoteplase, a single-bolus thrombolytic drug derived from alteplase tissue plasminogen activator, with the established accelerated alteplase regimen in patients presenting within 6 h of onset of ST elevation acute myocardial infarction. Methods and Results 15 078 patients were recruited from 855 hospitals worldwide and randomized in a 2:1 ratio to receive either lanoteplase 120 KU. kg-1 as a single intravenous bolus, or up to 100 mg accelerated alteplase given over 90 min. The primary end-point was all-cause mortality at 30 days and the hypothesis was that the two treatments would be equivalent. By 30 days, 6.61% of alteplase-treated patients and 6.75% lanoteplase-treated patients had died (relative risk 1.02). Total stroke occurred in 1.53% alteplase- and 1.87% lanoteplase-treated patients (ns); haemorrhagic stroke rates were 0.64% alteplase and 1.12% lanoteplase (P=0.004). The net clinical deficit of 30-day death or non-fatal disabling stroke was 7.0% and 7.2%, respectively. By 6 months, 8.8% of alteplase-treated patients and 8.7% of lanoteplase-treated patients had died. Conclusion Single-bolus weight-adjusted lanoteplase is an effective thrombolytic agent, equivalent to alteplase in terms of its impact on survival and with a comparable risk-benefit profile. The single-bolus regimen should shorten symptoms to treatment times and be especially convenient for emergency department or out-of-hospital administration. (C) 2000 The European Society of Cardiology